JPMorgan Chase & Co. (JPM) vs Eli Lilly and Company (LLY)

JPMorgan Chase & Co. is a leading global financial services company operating in 66 countries with more than 318,000 employees as of year-end 2025. Through its JPMorgan brands, the bank holding company reported a $4.9 trillion balance sheet and $2.68 trillion in deposits as of March 2026. Revenue is generated across three main business segments: Consumer & Community Banking, Commercial & Investment Bank, and Asset & Wealth Management. The firm holds the top global position in investment banking fees with an 8.4% market share, serves millions of customers through more than 5,000 U.S. branches, and oversees over $7.1 trillion in client assets in its wealth and asset management business.

Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.